DOP2003000759A - ADHESIVE COATED SHEET FOR DERMIC ADMINISTRATION OF A SELECTIVE CYCLLOXYGENASA-2 INHIBITOR - Google Patents

ADHESIVE COATED SHEET FOR DERMIC ADMINISTRATION OF A SELECTIVE CYCLLOXYGENASA-2 INHIBITOR

Info

Publication number
DOP2003000759A
DOP2003000759A DO2003000759A DO2003000759A DOP2003000759A DO P2003000759 A DOP2003000759 A DO P2003000759A DO 2003000759 A DO2003000759 A DO 2003000759A DO 2003000759 A DO2003000759 A DO 2003000759A DO P2003000759 A DOP2003000759 A DO P2003000759A
Authority
DO
Dominican Republic
Prior art keywords
subject
active agent
composition
skin
amount
Prior art date
Application number
DO2003000759A
Other languages
Spanish (es)
Inventor
Gary D Ewing
Guang Wei Lu
Brenda M Stoller
Kathryn M Kienle
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Priority to DO2003000759A priority Critical patent/DOP2003000759A/en
Publication of DOP2003000759A publication Critical patent/DOP2003000759A/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmaceutica para la aplicación sobre un area de piel de un sujeto para tratamiento local y/o sistemico de un trastorno mediado por COX-2 comprende una lamina de soporte que se puede adaptar flexiblemente al area de piel, teniendo la lamina de soporte superficies opuestas que son respectivamente distales y proximales a la piel cuando se aplica; y un revestimiento sobre la superficie proximal de la lamina de soporte que comprende (a) un adhesivo y (b) un agente activo que comprende valdecoxib o 1o uno de sus profarmacos o una de sus sales, estando el agente activo en una cantidad total terapeuticamente efectiva y disperso en una matriz que comprende de nada a menos de una cantidad efectiva que solubiliza un agente activo en total de uno o mas disolventes diferentes del adhesivo. Un procedimiento de tratamiento local de un sitio de dolor y/o inflamación en un sujeto comprende la aplicación de la composición sobre la superficie de piel del sujeto, preferiblemente en una localización superpuesta o adyacente al sitio de dolor y/o inflamación, y dejando la composición en el lugar durante un periodo de tiempo efectivo para permitir la liberación de una cantidad localmente terapeutica del agente activo. Un procedimiento de tratamiento sistemico de un sujeto que tiene un trastorno mediado por COX-2 comprende aplicar la composición sobre una superficie de piel del sujeto, y dejar la composición en el lugar durante un periodo de tiempo efectivo para permitir la liberación transdermica de una cantidad terapeutica del agente activo.A pharmaceutical composition for application on a skin area of a subject for local and / or systemic treatment of a COX-2 mediated disorder comprises a support foil that can be flexibly adapted to the skin area, the support foil having surfaces opposites that are respectively distal and proximal to the skin when applied; and a coating on the proximal surface of the support sheet comprising (a) an adhesive and (b) an active agent comprising valdecoxib or one of its prodrugs or one of its salts, the active agent being in a therapeutically total amount effective and dispersed in a matrix comprising nothing less than an effective amount that solubilizes a total active agent of one or more different solvents of the adhesive. A method of local treatment of a site of pain and / or inflammation in a subject comprises the application of the composition on the skin surface of the subject, preferably in a location superimposed or adjacent to the site of pain and / or inflammation, and leaving the composition in place for an effective period of time to allow the release of a locally therapeutic amount of the active agent. A method of systematic treatment of a subject having a COX-2 mediated disorder comprises applying the composition on a subject's skin surface, and leaving the composition in place for an effective period of time to allow transdermal release of an amount. Therapeutics of the active agent.

DO2003000759A 2003-11-20 2003-11-20 ADHESIVE COATED SHEET FOR DERMIC ADMINISTRATION OF A SELECTIVE CYCLLOXYGENASA-2 INHIBITOR DOP2003000759A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DO2003000759A DOP2003000759A (en) 2003-11-20 2003-11-20 ADHESIVE COATED SHEET FOR DERMIC ADMINISTRATION OF A SELECTIVE CYCLLOXYGENASA-2 INHIBITOR

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DO2003000759A DOP2003000759A (en) 2003-11-20 2003-11-20 ADHESIVE COATED SHEET FOR DERMIC ADMINISTRATION OF A SELECTIVE CYCLLOXYGENASA-2 INHIBITOR

Publications (1)

Publication Number Publication Date
DOP2003000759A true DOP2003000759A (en) 2004-07-15

Family

ID=44261254

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2003000759A DOP2003000759A (en) 2003-11-20 2003-11-20 ADHESIVE COATED SHEET FOR DERMIC ADMINISTRATION OF A SELECTIVE CYCLLOXYGENASA-2 INHIBITOR

Country Status (1)

Country Link
DO (1) DOP2003000759A (en)

Similar Documents

Publication Publication Date Title
AR042104A1 (en) ADHESIVE COATED SHEET FOR DERMIC ADMINISTRATION OF A CYCLOOXYGENASE SELECTIVE INHIBITOR -2
AR048827A1 (en) APPARATUS AND METHOD FOR THE TRANSDERMAL ADMINISTRATION OF FENTANIL-BASED AGENTS
AR046697A1 (en) METHOD AND SYSTEM OF TRANSDERMAL ADMINISTRATION OF AGENT ASSISTED BY FREQUENCY
JP2017039781A5 (en)
HUP0401281A2 (en) Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals
BR0312671A (en) Micro-needle device, method for using a micro-needle device, and method for applying a micro-needle device
EP2001453A4 (en) Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
MXPA06013168A (en) Apparatus and method for transdermal delivery of parathyroid hormone agents.
TW200618830A (en) Micorprojection apparatus and system with low infection potential
AR046824A1 (en) COMPOSITION AND APPLIANCE FOR TRANSDERMAL ADMINISTRATION.
TW200502017A (en) Active agent delivery device having composite members
JP2006525316A5 (en)
MX2009013574A (en) Modified release solid or semi-solid dosage forms.
WO2010009116A3 (en) Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
AR042102A1 (en) DERMIC ADMINISTRATION OF A CYCLLOXYGENASA INHIBITOR - 2 WATER SOLUBLE SELECTIVE
BRPI0415986A (en) method and apparatus for reducing the incidence of tobacco use
BRPI0417437A (en) absorption inhibiting device, physiologically active agent removal device and overdose reduction device
MX2012002727A (en) Transdermal therapeutic system for administering fentanyl or an analogue thereof.
JP2006525315A5 (en)
BR0316436A (en) Cyclooxygenase-2 Selective Inhibitor Plaster
DOP2003000759A (en) ADHESIVE COATED SHEET FOR DERMIC ADMINISTRATION OF A SELECTIVE CYCLLOXYGENASA-2 INHIBITOR
PA8615501A1 (en) PHARMACEUTICAL FORMULATIONS TRANSDERMICAS
AR054225A1 (en) APPARATUS AND METHOD FOR TRANSDERMAL SUPPLY OF EPOYETINE-BASED AGENTS
AR127966A1 (en) TOPICAL FORMULATIONS OF PI3K-DELTA INHIBITORS
DOP2003000758A (en) DERMIC ADMINISTRATION OF A WATER SOLUBLE SELECTIVE CYCLLOXYGENASA-2 INHIBITOR